|
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies Clinical research trials and Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies. Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "U" Clinical Trials Conditions > Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies  Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
For Condition: plasma cell neoplasm,Lymphoma,Leukemia,chronic myeloproliferative disorders,myelodysplastic and myeloproliferative diseases
Status: Recruiting
Sponsor(s): Ireland Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body’s normal cells. Ultraviolet-B light therapy given before and after allogeneic stem cell transplantation may help prevent this from happening. PURPOSE: Clinical trial to study the effectiveness of combining ultraviolet-B light therapy with allogeneic stem cell transplantation in treating patients who have hematologic malignancies.
Details: OBJECTIVES: Primary - Determine the safety of ultraviolet-B light therapy and allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies by demonstrating 100-day mortality no greater than 15% and 1-year mortality no greater than 40%. - Determine the frequency of treatment-related toxicity leading to death and frequency of disease relapse resulting in death in patients treated with this regimen. - Determine the incidence and severity of acute and chronic graft-versus-host disease in patients treated with this regimen. Secondary - Determine the rates of donor allogeneic hematologic engraftment in patients treated with this regimen. - Determine the rate and quality of immune reconstitution in the peripheral blood and the composition of immune cells in the skin before and after transplantation in these patients. - Determine the event-free and overall survival of patients treated with this regimen. OUTLINE: - Preparative regimen: Patients receive fludarabine IV over 30 minutes on days -8 to -4 and cyclophosphamide IV over 1 hour on days -3 to -2. Patients also receive anti-thymocyte globulin IV over 4 hours on days -2 to -1. Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. - Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0. - Graft-versus-host disease prophylaxis: Patients receive oral cyclosporine on days -1 to 100 and methylprednisolone (oral or IV) on days 5-15. - Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4. Donor lymphocyte infusion is performed per institutional guidelines for patients in whom emerging donor chimerism post allogeneic PBSC transplantation is not progressing (consistently below 50% during first 3 months), for whom donor chimerism is receding (to below 25%) despite cessation of cyclosporine, or who relapse within 24 months after allografting. Patients are followed at least monthly for 3 months and then at 6, 12, 18, and 24 months. PROJECTED ACCRUAL: A total of 23-36 patients will be accrued for this study.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed diagnosis of any of the following hematologic malignancies: - Acute myeloid leukemia (AML) meeting any of the following criteria: - First complete remission with high-risk karyotype - Translocations t(15;17) allowed only if failed first-line induction therapy OR molecular evidence of persistent disease exists - Translocations t(8;21) and inv(16) allowed only if failed first-line induction therapy - Second or subsequent complete remission - Minimal residual disease* - Acute lymphoblastic leukemia meeting any of the following criteria: - Failed induction therapy and has minimal residual disease* by salvage therapy - First complete remission with high-risk karyotype (e.g., t[4;11] or t[9;22]) - Relapsed disease allowed provided a second or subsequent complete remission or minimal residual disease* is achieved - Chronic myelogenous leukemia meeting any of the following criteria: - Persistent or relapsed disease after 1 year of imatinib mesylate therapy - Accelerated phase or blast crisis - Blast crisis allowed after reinduction chemotherapy places disease in chronic phase - Myelodysplastic syndromes meeting any of the following criteria: - Refractory to medical management - Cytogenetic abnormalities predictive of transformation into acute leukemia, including 5q-, 7q-, monosomy 7 and trisomy 8, or evidence of evolution to AML (e.g., refractory anemia with excess blasts (RAEB) or RAEB in transformation) - Non-Hodgkin's lymphoma or Hodgkin's lymphoma meeting any of the following criteria: - Beyond first complete remission or failed primary induction therapy and demonstrated sensitivity to therapy during the 6 months before transplantation - Recurrent disease after autologous stem cell transplantation - Must be at least 3 months posttransplantation - Cyclin D1+ mantle cell lymphoma allowed after induction therapy and in first remission - Multiple myeloma meeting either of the following criteria: - Refractory or relapsed disease - Residual disease after autologous transplantation - Chronic lymphocytic leukemia (CLL) meeting all of the following criteria: - Peripheral blood absolute lymphocyte count greater than 5,000/mm^3 - Small to moderate size lymphocytes and less than 55% pro-lymphocytes, atypical lymphocytes, or lymphoblasts morphologically - B-cell or T-cell - Myeloproliferative disorders, including myelofibrosis - Philadelphia negative - Availability of a HLA-A, B, and DR identical family donor OR HLA-A, B, and DR genetically matched unrelated donor - Must meet 1 of the following criteria: - At least 55 years of age at time of transplantation - Received extensive prior therapy (i.e., more than 1 year of alkylator therapy or more than 2 different prior salvage regimens) or stem cell transplantation with myeloablative conditioning (either autologous or allogeneic) - Presenting with comorbid condition (e.g., abnormal cardiac, pulmonary, or renal function and/or prior life-threatening infection) that precludes eligibility for enrollment in allogeneic transplantation protocols with full ablation conditioning - No active CNS disease NOTE: *Defined as having no circulating blasts, absolute neutrophil count greater than 1,000/mm3 and less than 10% blasts in bone marrow at least 3 weeks after last systemic chemotherapy PATIENT CHARACTERISTICS: Age - See Disease Characteristics - Over 18 Performance status - ECOG 0-2 Life expectancy - At least 3 months Hematopoietic - See Disease Characteristics Hepatic - Bilirubin no greater than 2.0 mg/dL - ALT/AST no greater than 4 times normal Renal - See Disease Characteristics - Creatinine less than 2.0 mg/dL OR - Creatinine clearance at least 50 mL/min Cardiovascular - See Disease Characteristics - Normal cardiac function by echocardiogram or radionuclide scan - Shortening fraction or ejection fraction at least 40% of normal Pulmonary - See Disease Characteristics - DLCO at least 60% - FEV_1 greater than 50% of predicted - Pulse oximetry greater than 85% Other - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - HIV negative - No uncontrolled active infection PRIOR CONCURRENT THERAPY: Biologic therapy - See Disease Characteristics - At least 2 weeks since prior biologic response modifiers, signal transduction inhibitors, or monoclonal antibodies Chemotherapy - See Disease Characteristics - At least 4 weeks since prior systemic conventional chemotherapy Endocrine therapy - Not specified Radiotherapy - Not specified Surgery - Not specified Other - Recovered from prior therapy - No concurrent sun block/sunscreen or any cosmetic that may act as a sunscreen (e.g., lotion with SPF) on the days of scheduled ultraviolet-B light therapy
Total Enrollment:
Location and Contact Information:
Overall Study Official:
OmerKoc, Principal Investigator, Ireland Cancer Center
Ireland Cancer Center *Recruiting*
Cleveland, Ohio, 44106
United States
Recruiting Omer Koc 216-244-1274
Additional Information:
Study ID Numbers: CDR0000327713; CWRU-ICC-7Y02
Study Start Date:
Record last reviewed: October 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00068523
Other Myelodysplastic And Myeloproliferative Diseases Studies:
1. Total-Body Irradiation, Cyclophosphamide, and Stem Cell Transplantation in Treating Patients With Hematologic Cancer
2. T-Cell-Depleted Allogeneic Stem Cell Transplantation Followed By Treated Donor T Cells After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
3. Donor Stem Cell Transplantation in Treating Patients With Relapsed Hematologic Cancer
4. Donor Stem Cell Transplantation in Treating Patients With Hematologic Cancer
5. Umbilical Cord Blood Transplantation in Treating Patients With High-Risk Hematologic Cancer
Related Studies:
Other myelodysplastic and myeloproliferative diseases Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies
|
|
|
|
|
|
|
|
